Kallikreins and proteinase-mediated signaling: Proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer

Biological Chemistry

Volumn 389, Issue 6, 2008, Pages 643-651

  Hollenberg, Morley D ^a   Oikonomopoulou, Katerina ^b,c   Hansen, Kristina K ^a   Saifeddine, Mahmoud ^a   Ramachandran, Rithwik ^a   Diamandis, Eleftherios P ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Arthritis; Coagulation cascade; Colitis; Pain; Thrombin; Trypsin

Indexed keywords

CALCIUM; KALLIKREIN; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; THROMBIN RECEPTOR; TRYPSIN;

ARTHRITIS; CALCIUM CELL LEVEL; CARDIOVASCULAR FUNCTION; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; INFLAMMATORY DISEASE; METASTASIS; NEOPLASM; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; INFLAMMATION; KALLIKREINS; NEOPLASMS; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION;

EID: 47549113638     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.077     Document Type: Conference Paper

References (84)

1. Al-Ani, B., Saifeddine, M., and Hollenberg, M.D. (1995). Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. Can. J. Physiol. Pharmacol. 73, 1203-1207.
2. Antalis, T.M., Shea-Donohue, T., Vogel, S.N., Sears, C., and Fasano, A. (2007). Mechanisms of disease: protease functions in intestinal mucosal pathobiology. Nat. Clin. Pract. Gastroenterol. Hepatol. 4, 393-402.
3. Asfaha, S., Brussee, V., Chapman, K., Zochodne, D.W., and Vergnolle, N. (2002). Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br. J. Pharmacol. 135, 1101-1106.
4. Becker, C., Noldus, J., Diamandis, E., and Lilja, H. (2001). The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit. Rev. Clin. Lab. Sci. 38, 357-399.
5. Bhattacharjee, G., Ahamed, J., Pawlinski, R., Liu, C., Mackman, N., Ruf, W., and Edgington, T.S. (2008). Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ. Res. 102, 457-464.
6. Blanc-Brude, O.P., Archer, F., Leoni, P., Derian, C., Bolsover, S., Laurent, G.J., and Chambers, R.C. (2005). Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp. Cell Res. 304, 16-27.
7. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313.
8. Borgoño, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
9. Borgoño, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
10. Boven, L.A., Vergnolle, N., Henry, S.D., Silva, C., Imai, Y., Holden, J., Warren, K., Hollenberg, M.D., and Power, C. (2003). Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J. Immunol. 170, 2638-2646.
11. Burger, M.M. (1970). Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 227, 170-171.
12. Bushell, T. (2007). The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders. J. Physiol. 581, 7-16.
13. Camerer, E. (2007). Unchecked thrombin is bad news for troubled arteries. J. Clin. Invest. 117, 1486-1489.
14. Cenac, N., Coelho, A.M., Nguyen, C., Compton, S., Andrade-Gordon, P., MacNaughton, W.K., Wallace, J.L., Hollenberg, M.D., Bunnett, N.W., Garcia-Villar, R., et al. (2002). Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161, 1903-1915.
15. Cenac, N., Andrews, C.N., Holzhausen, M., Chapman, K., Cottrell, G., Andrade-Gordon, P., Steinhoff, M., Barbara, G., Beck, P., Bunnett, N.W., et al. (2007). Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest. 117, 636-647.
16. Chackalamannil, S., Xia, Y., Greenlee, W.J., Clasby, M., Doller, D., Tsai, H., Asberom, T., Czarniecki, M., Ahn, H.S., Boykow, G., et al. (2005). Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 48, 5884-5887.
17. Chen, L.B. and Buchanan, J.M. (1975). Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc. Natl. Acad. Sci. USA 72, 131-135.
18. Corvera, C.U., Dery, O., McConalogue, K., Gamp, P., Thoma, M., Al-Ani, B., Caughey, G.H., Hollenberg, M.D., and Bunnett, N.W. (1999). Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. J. Physiol. 517, 741-756.
19. Coughlin, S.R. (2005). Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814.
20. Covic, L., Misra, M., Badar, J., Singh, C., and Kuliopulos, A. (2002). Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8, 1161-1165.
21. Cushman, D.W. and Ondetti, M.A. (1999). Design of angiotensin converting enzyme inhibitors. Nat. Med. 5, 1110-1113.
22. Damiano, B.P., Cheung, W.M., Santulli, R.J., Fung-Leung, W.P., Ngo, K., Ye, R.D., Darrow, A.L., Derian, C.K., de Garavilla, L., and Andrade-Gordon, P. (1999). Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J. Pharmacol. Exp. Ther. 288, 671-678.
23. de Garavilla, L., Vergnolle, N., Young, S.H., Ennes, H., Steinhoff, M., Ossovskaya, V.S., D'Andrea, M.R., Mayer, E.A., Wallace, J.L., Hollenberg, M.D., et al. (2001). Agonists of proteinaseactivated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br. J. Pharmacol. 133, 975-987.
24. Dulon, S., Cande, C., Bunnett, N.W., Hollenberg, M.D., Chignard, M., and Pidard, D. (2003). Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. Am. J. Respir. Cell. Mol. Biol. 28, 339-346.
25. Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, Y., Reich, R., Vlodavsky, I., and Bar-Shavit, R. (1998). Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 4, 909-914.
26. Felber, L.M., Kündig, C., Borgoño, C.A., Chagas, J.R., Tasinato, A., Jichlinski, P., Gygi, C.M., Leisinger, H.J., Diamandis, E.P., Deperthes, D., and Cloutier, S.M. (2006). Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. FEBS J. 273, 2505-2514.
27. Ferrell, W.R., Lockhart, J.C., Kelso, E.B., Dunning, L., Plevin, R., Meek, S.E., Smith, A.J., Hunter, G.D., McLean, J.S., McGarry, F., et al. (2003). Essential role for proteinase-activated receptor-2 in arthritis. J. Clin. Invest. 111, 35-41.
28. Gui, Y., Loutzenhiser, R., and Hollenberg, M.D. (2003). Bidirectional regulation of renal hemodynamics by activation of PAR1 and PAR2 in isolated perfused rat kidney. Am. J. Physiol. Renal Physiol. 285, F95-104.
29. Hansen, K.K., Sherman, P.M., Cellars, L., Andrade-Gordon, P., Pan, Z., Baruch, A., Wallace, J.L., Hollenberg, M.D., and Vergnolle, N. (2005). A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc. Natl. Acad. Sci. USA 102, 8363-8368.
30. Hansen, K.K., Oikonomopoulou, K., Li, Y., and Hollenberg, M.D. (2007). Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems. Naunyn-Schmiedeberg's Arch. Pharmacol., in press, DOI: 10.1007/s00210-007-0194-2.
31. Hawkins, J.V., Emmel, E.L., Feuer, J.J., Nedelman, M.A., Harvey, C.J., Klein, H.J., Rozmiarek, H., Kennedy, A.R., Lichtenstein, G.R., and Billings, P.C. (1997). Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig. Dis. Sci. 42, 1969-1980.
32. Henrikson, K.P., Salazar, S.L., Fenton, J.W. II, and Pentecost, B.T. (1999). Role of thrombin receptor in breast cancer invasiveness. Br. J. Cancer 79, 401-406.
33. Hollenberg, M.D. and Compton, S.J. (2002). International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Rev. 54, 203-217.
34. Hollenberg, M.D. and Saifeddine, M. (2001). Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can. J. Physiol. Pharmacol. 79, 439-442.
35. Hollenberg, M.D., Saifeddine, M., Sandhu, S., Houle, S., and Vergnolle, N. (2004). Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br. J. Pharmacol. 143, 443-454.
36. Houle, S., Papez, M.D., Ferazzini, M., Hollenberg, M.D., and Vergnolle, N. (2005). Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br. J. Pharmacol. 146, 670-678.
37. Kawabata, A., Saifeddine, M., Al-Ani, B., Leblond, L., and Hollenberg, M.D. (1999). Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J. Pharmacol. Exp. Ther. 288, 358-370.
38. Kelso, E.B., Lockhart, J.C., Hembrough, T., Dunning, L., Plevin, R., Hollenberg, M.D., Sommerhoff, C.P., McLean, J.S., and Ferrell, W.R. (2006). Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J. Pharmacol. Exp. Ther. 316, 1017-1024.
39. Kimura, M., Andersen, T.T., Fenton, J.W. II, Bahou, W.F., and Aviv, A. (1996). Plasmin-platelet interaction involves cleavage of functional thrombin receptor. Am. J. Physiol. 271, C54-60.
40. Kong, W., McConalogue, K., Khitin, L.M., Hollenberg, M.D., Payan, D.G., Böhm, S.K., and Bunnett, N.W. (1997). Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc. Natl. Acad. Sci. USA 94, 8884-8889.
41. Kono, T. and Barham, F.W. (1971). Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. J. Biol. Chem. 246, 6204-6209.
42. 1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 38, 4572-4585.
43. Laumonnier, Y., Syrovets, T., Burysek, L., and Simmet, T. (2006). Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood 107, 3342-3349.
44. Li, Q., Laumonnier, Y., Syrovets, T., and Simmet, T. (2007). Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 27, 1383-1389.
45. Maryanoff, B.E., Zhang, H.C., Andrade-Gordon, P., and Derian, C.K. (2003). Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr. Med. Chem. Cardiovasc. Hematol. Agents 1, 13-36.
46. McGuire, J.J., Hollenberg, M.D., Bennett, B.M., and Triggle, C.R. (2004) Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. Can. J. Physiol. Pharmacol. 82, 1103-1112.
47. Moffatt, J.D. (2007). Proteinase-activated receptors in the lower urinary tract. Naunyn-Schmiedeberg's Arch. Pharmacol. 375, 1-9.
48. Muramatsu, I., Laniyonu, A., Moore, G.J., and Hollenberg, M.D. (1992). Vascular actions of thrombin receptor peptide. Can. J. Physiol. Pharmacol. 70, 996-1003.
49. Napoli, C., Cicala, C., Wallace, J.L., de Nigris, F., Santagada, V., Caliendo, G., Franconi, F., Ignarro, L.J., and Cirino, G. (2000). Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc. Natl. Acad. Sci. USA 97, 3678-3683.
50. Napoli, C., de Nigris, F., Wallace, J.L., Hollenberg, M.D., Tajana, G., De Rosa, G., Sica, V., and Cirino, G. (2004). Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions. J. Clin. Pathol. 57, 513-516.
51. Nierodzik, M.L., Chen, K., Takeshita, K., Li, J.J., Huang, Y.Q., Feng, X.S., D'Andrea, M.R., Andrade-Gordon, P., and Karpatkin, S. (1998). Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92, 3694-3700.
52. Noorbakhsh, F., Vergnolle, N., McArthur, J.C., Silva, C., Vodjgani, M., Andrade-Gordon, P., Hollenberg, M.D., and Power, C. (2005). Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J. Immunol. 174, 7320-7329.
53. Noorbakhsh, F., Tsutsui, S., Vergnolle, N., Boven, L.A., Shariat, N., Vodjgani, M., Warren, K.G., Andrade-Gordon, P., Hollenberg, M.D., and Power, C. (2006). Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203, 425-435.
54. Nystedt, S., Emilsson, K., Wahlestedt, C., and Sundelin, J. (1994). Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. USA 91, 9208-9212.
55. Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G.S., Bunnett, N.W., et al. (2006a). Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281, 32095-32112.
56. Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Vergnolle, N., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Diamandis, E.P., and Hollenberg, M.D. (2006b). Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol. Chem. 387, 817-824.
57. Ossovskaya, V.S. and Bunnett, N.W. (2004). Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84, 579-621.
58. Quinton, T.M., Kim, S., Derian, C.K., Jin, J., and Kunapuli, S.P. (2004). Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J. Biol. Chem. 279, 18434-18439.
59. Ramachandran, R. and Hollenberg, M.D. (2008). Proteinases and signaling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 153, S263-S282.
60. 2+ mobilization. FEBS Lett. 288, 123-128.
61. Rieser, P. (1967). The insulin-like action of pepsin and pepsinogen. Acta Endocrinol. (Copenh). 54, 375-379.
62. Rieser, P. and Rieser, C.H. (1964). Anabolic responses of diaphragm muscle to insulin and to other pancreatic proteins. Proc. Soc. Exp. Biol. Med. 116, 669-671.
63. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M., and Ruf, W. (2002). Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880-1882.
64. Roviezzo, F., Bucci, M., Brancaleone, V., Di Lorenzo, A., Geppetti, P., Farneti, S., Parente, L., Lungarella, G., Fiorucci, S., and Cirino, G. (2005). Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler. Thromb. Vasc. Biol. 25, 2349-2354.
65. Ruf, W., Dorfleutner, A., and Riewald, M. (2003). Specificity of coagulation factor signaling. J. Thromb. Haemost. 1, 1495-1503.
66. Saifeddine, M., Al-Ani, B., Cheng, C.H., Wang, L., and Hollenberg, M.D. (1996). Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br. J. Pharmacol. 118, 521-530.
67. Sefton, B.M. and Rubin, H. (1970). Release from density dependent growth inhibition by proteolytic enzymes. Nature 227, 843-845.
68. Shapiro, S.D. (1999). Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth. Thromb. Haemost. 82, 846-849.
69. Shaw, J.L. and Diamandis, E.P. (2007). Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53, 1423-1432.
70. Shi, X., Gangadharan, B., Brass, L.F., Ruf, W., and Mueller, B.M. (2004). Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol. Cancer Res. 2, 395-402.
71. Shoelson, S.E., White, M.F., and Kahn, C.R. (1988). Tryptic activation of the insulin receptor. Proteolytic truncation of the α-subunit releases the β-subunit from inhibitory control. J. Biol. Chem. 263, 4852-4860.
72. Steinhoff, M., Vergnolle, N., Young, S.H., Tognetto, M., Amadesi, S., Ennes, H.S., Trevisani, M., Hollenberg, M.D., Wallace, J.L., Caughey, G.H., et al. (2000). Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat. Med. 6, 151-158.
73. Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moormann, C., Vergnolle, N., Luger, T.A., and Hollenberg, M.D. (2005). Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev. 26, 1-43.
74. Vergnolle, N. (2004). Modulation of visceral pain and inflammation by protease-activated receptors. Br. J. Pharmacol. 141, 1264-1274.
75. Vergnolle, N. (2005). Clinical relevance of proteinase activated receptors (PARs) in the gut. Gut 54, 867-874.
76. Vergnolle, N., Hollenberg, M.D., Sharkey, K.A., and Wallace, J.L. (1999a). Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127, 1083-1090.
77. Vergnolle, N., Hollenberg, M.D., and Wallace, J.L. (1999b). Pro-and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). Br. J. Pharmacol. 126, 1262-1268.
78. Vergnolle, N., Bunnett, N.W., Sharkey, K.A., Brussee, V., Compton, S.J., Grady, E.F., Cirino, G., Gerard, N., Basbaum, A.I., Andrade-Gordon, P., et al. (2001a). Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat. Med. 7, 821-826.
79. Vergnolle, N., Wallace, J.L., Bunnett, N.W., and Hollenberg, M.D. (2001b). Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci. 22, 146-152.
80. Vergnolle, N., Derian, C.K., D'Andrea, M.R., Steinhoff, M., and Andrade-Gordon, P. (2002). Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J. Immunol. 169, 1467-1473.
81. Versteeg, H.H. and Ruf, W. (2006). Emerging insights in tissue factor-dependent signaling events. Semin. Thromb. Hemost. 32, 24-32.
82. Vu, T.K., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057-1068.
83. Wang, X., Hollenberg, M.D., and Loutzenhiser, R. (2005). Redundant signaling mechanisms contribute to the vasodilatory response of the afferent arteriole to proteinase-activated receptor-2. Am. J. Physiol. Renal Physiol. 288, F65-75.
84. Yang, L., Bae, J.S., Manithody, C., and Rezaie, A.R. (2007). Identification of a specific exosite on activated protein C for interaction with protease activated receptor 1. J. Biol. Chem. 282, 25493-25500.